DiaMedica Therapeutics Inc.
DMAC
Rank in Stocks
#11875
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical... DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Share Price
$9.65
Last synced: 2026-11-09
Market Cap
$520.38M
Change (1 day)
3.10%
Change (1 year)
52.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade DiaMedica Therapeutics Inc. (DMAC)
Category
Healthcare
Operating Margin for DiaMedica Therapeutics Inc. (DMAC)
Operating Margin as of November 2026 TTM: 0.00%
According to DiaMedica Therapeutics Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for DiaMedica Therapeutics Inc. from 2004 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -1,352.20% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | -100.00% |
| 2007 | -1,438.05% | -52.98% |
| 2006 | -3,058.67% | 286.90% |
| 2005 | -790.56% | -55.61% |
| 2004 | -1,781.04% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about DiaMedica Therapeutics Inc.'s operating margin
What was DiaMedica Therapeutics Inc.'s operating margin in 2025?
In 2025, DiaMedica Therapeutics Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has DiaMedica Therapeutics Inc.'s operating margin changed since 2020?
From 2020 to 2025, DiaMedica Therapeutics Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does DiaMedica Therapeutics Inc.'s operating margin compare with similar companies?
DiaMedica Therapeutics Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.